›Portfolio Companies

Past, Present and Future Leaders

InterWest is proud and privileged to partner with visionary management teams who are shaping the future of Information Technology and Healthcare. The companies they have started are vital parts of the portfolio of industry-leading startups that InterWest has helped over the last four decades.

Our Companies


467 First Street, Suite 201
Los Altos, CA 94022, USA
T: 650-854-8585
F: 650-854-4706

Early stage IT and Healthcare Investing

Gil Kliman


Managing Partner

"It’s a privilege to work with visionary entrepreneurs who are creating the technologies and procedures that define the future of medical care. And it’s exciting to help them craft business strategies that propel and transform their ideas into market penetration and real-world success."

InterWest Team

Current Investments

Prior Investments

Follow Gil

Gil's bio

Company News


Gil's video

Gil joined InterWest in 1996. As a managing partner of the firm and the leader of InterWest’s Healthcare investment team, he invests in a broad array of healthcare opportunities, with a special interest in ophthalmology, digital health, and AI/robotics. Gil pioneered InterWest’s highly successful ophthalmology franchise. He was an early investor in Avedro, Glaukos, LenSx, and IntraLase-category-creating ophthalmic companies that became standard-of-care for eye surgery around the world.


As a successful digital health investor, Gil built this important franchise for InterWest over the last twenty years through multiple companies. He was the founding institutional investor in Doximity, helping to build it into the leading physician social network, engaging over 80% of U.S. physicians, with over one million users, and helping it to execute its June 2021 blockbuster IPO, positioning it to be the largest return investment in InterWest’s history. Prior to that, he led the Series A of Epocrates, the first mobile application for physicians, serving on the board through its 2011 IPO.


 He is a board member of Doximity (NYSE: DOCS), Glaukos (NYSE: GKOS), and a former board member and lead investor in Avedro (NASDAQ: AVDR, acquired by Glaukos), Epocrates (EPOC, acquired by Athenahealth), LenSx Lasers (acquired by Alcon), IntraLase (NASDAQ: ILSE, acquired by AMO), Neuronetics (NASDAQ: STIM), Restoration Robotics (NASDAQ: VERO, acquired by Venus Concept), and GoCheck.


Gil also serves as an independent board member of STAAR Surgical (NASDAQ: STAA), Centricity Vision and Orbis International, a global not-for-profit organization focused on preventing blindness. He is also a co-founder and program director of Eyecelerator, a first-of-kind ophthalmology innovation conference supported by a joint venture of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Its mission is to spur innovation in the ophthalmology sector by connecting scientific talent and entrepreneurs advancing eye care with mission-driven investors and business partners who can support go-to-market success. Previously, he helped to launch the Ophthalmology Innovation Summit (OIS), an ophthalmology business conference where he was an advisor and founding co-chairman from 2009 to 2019.


A former practicing ophthalmologist, Gil completed an ophthalmology residency at Wills Eye Hospital and a retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Foundation fellow. He has a BA from Harvard University, an MD from the University of Pennsylvania and an MBA from Stanford University.

Over the last 20 years I have had the privilege of diverse life experiences as a laser researcher, practicing physician, startup company founder, and technology venture capitalist. I most enjoy being on the front edge of new technology waves, looking over the horizon for non-obvious opportunities... What I find exciting is working alongside visionary entrepreneurs, thinking non-traditionally, and helping to identify creative strategies to make pioneering ventures even more successful.

Information Technology

Facebook Google+ Twitter Email LinkedIn Share